ArticleInfection2021
Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy.
Article in Infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Status and outlook of pulmonary tuberculosis coinfection.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Concomitant tuberculosis and aspergillosis in patients with COVID-19: a case report.Iranian journal of microbiology · 2024Article
- Diverse interactions ofFrontiers in tuberculosis · 2024Review
- COVID-19 and tuberculosis coinfection: An overview of case reports/case series and meta-analysis of prevalence studies.Heliyon · 2023Review
- Initial immune response after exposure toFrontiers in immunology · 2023Review
- Multiple CD59 Polymorphisms in Chinese Patients withJournal of immunology research · 2023Article
- Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review.Journal of clinical medicine · 2022Review
- Tuberculosis Disability Adjusted Life Years, Colombia 2010-2018.Tropical medicine and infectious disease · 2022Article
- Impact of COVID-19 on Tuberculosis Indicators in Brazil: A Time Series and Spatial Analysis Study.Tropical medicine and infectious disease · 2022Article
- Article
- Integrated Tuberculosis and COVID-19 Activities in Karachi and Tuberculosis Case Notifications.Tropical medicine and infectious disease · 2022Article
- Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey.Le infezioni in medicina · 2022Article
- Tuberculosis and COVID-19 co-infection in Serbia: Pandemic challenge in a low-burden country.Frontiers in medicine · 2022Article
- COVID-19 and Pulmonary Tuberculosis Coinfection in a Moroccan Patient with Pulmonary Embolism: A Case Report and Literature Review.Case reports in infectious diseases · 2022Article
- Pulmonary tuberculosis and COVID-19 coinfection: Hickam's Dictum revisited.Respiratory medicine case reports · 2022Article
- Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- The definition of tuberculosis infection based on the spectrum of tuberculosis disease.Breathe (Sheffield, England) · 2021Review
- Triple infection with disseminated tuberculosis, invasive aspergillosis and COVID-19 in an organ transplant recipient with iatrogenic immunosuppression.BMJ case reports · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Funding
Abstract
Tuberculosis (TB) is top infectious disease killer caused by a single organism responsible for 1.5 million deaths in 2018. Both COVID-19 and the pandemic response are risking to affect control measures for TB and continuity of essential services for people affected by this infection in western countries and even more in developing countries. Knowledge about concomitant pulmonary TB and COVID-19 is extremely limited. The double burden of these two diseases can have devastating effects. Here, we describe from both the clinical and the immunological point of view a case of a patient with in vitro immune cell anergy affected by bilateral cavitary pulmonary TB and subsequent COVID-19-associated pneumonia with a worst outcome. COVID-19 can be a precipitating factor in TB respiratory failure and, during ongoing SARS-COV-2 pandemic, clinicians must be aware of this possible co-infection in differential diagnosis of patients with active TB and new or worsening chest imaging.
Indexed as
Identifiers
33454928PMC7811686W3121874636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.